Meanwhile, VEGF-targeted RNAi using poly-siRNA/tGC NPs in combination with chemotherapeutic agents can control tumor growth by increasing anti-angiogenic efficacy while minimizing toxicity and drug resistance (Kwak et al., 2017). This evidence concerns the gene VEGFA and neoplasm.